Results 161 to 170 of about 419,478 (257)
Nanoparticle-Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology. [PDF]
Baker AG, Ho APT, Itzhaki LS, Fruk L.
europepmc +1 more source
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj +21 more
wiley +1 more source
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation. [PDF]
Zhao J, Chen H, Liang C.
europepmc +1 more source
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv +10 more
wiley +1 more source
A spleen‐targeting hybrid nanoplatform (RBCMV‐LNP‐RP) harnessing erythrophagocytosis mimics senescent red blood cell clearance to achieve spleen‐specific delivery of rapamycin. This biomimetic system enables selective accumulation in splenic macrophages, orchestrating systemic immune reprogramming and promoting mucosal healing in an inflammatory bowel ...
Jun Kwon +10 more
wiley +1 more source
Recent advances in glutarimide chemistry for cereblon-mediated targeted protein degradation: developments in synthesis and diversification. [PDF]
Ba X +3 more
europepmc +1 more source
A multivalent antiviral platform based on honeycomb‐shaped DNA nanostructures (HC–Urumin) is developed to enhance the potency and breadth of the host defense peptide Urumin. Through spatially patterned trimeric presentation, HC–Urumin disrupts influenza A virus entry, improves cell viability, and reduces disease severity in vivo‐offering a modular and ...
Saurabh Umrao +11 more
wiley +1 more source
A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo +7 more
wiley +1 more source
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation. [PDF]
Zheng Y +13 more
europepmc +1 more source

